Efaproxiral

Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Efaproxiral

Articles

Most recent articles on Efaproxiral

Most cited articles on Efaproxiral

Review articles on Efaproxiral

Articles on Efaproxiral in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Efaproxiral

Images of Efaproxiral

Photos of Efaproxiral

Podcasts & MP3s on Efaproxiral

Videos on Efaproxiral

Evidence Based Medicine

Cochrane Collaboration on Efaproxiral

Bandolier on Efaproxiral

TRIP on Efaproxiral

Clinical Trials

Ongoing Trials on Efaproxiral at Clinical Trials.gov

Trial results on Efaproxiral

Clinical Trials on Efaproxiral at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Efaproxiral

NICE Guidance on Efaproxiral

NHS PRODIGY Guidance

FDA on Efaproxiral

CDC on Efaproxiral

Books

Books on Efaproxiral

News

Efaproxiral in the news

Be alerted to news on Efaproxiral

News trends on Efaproxiral

Commentary

Blogs on Efaproxiral

Definitions

Definitions of Efaproxiral

Patient Resources / Community

Patient resources on Efaproxiral

Discussion groups on Efaproxiral

Patient Handouts on Efaproxiral

Directions to Hospitals Treating Efaproxiral

Risk calculators and risk factors for Efaproxiral

Healthcare Provider Resources

Symptoms of Efaproxiral

Causes & Risk Factors for Efaproxiral

Diagnostic studies for Efaproxiral

Treatment of Efaproxiral

Continuing Medical Education (CME)

CME Programs on Efaproxiral

International

Efaproxiral en Espanol

Efaproxiral en Francais

Business

Efaproxiral in the Marketplace

Patents on Efaproxiral

Experimental / Informatics

List of terms related to Efaproxiral

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]

Overview

Efaproxiral (INN) is an analogue of the cholesterol drug bezafibrate developed for the treatment of depression, traumatic brain injury, ischemia, stroke, myocardial infarction, diabetes, hypoxia, sickle cell disease, hypercholesterolemia and as a radio sensitiser.[1][2][3] The chemical is a propanoic acid in the class of amphipathic carboxylic acids. Most propanoic acid produced is consumed as a preservative for both animal feed and food for human consumption. One use for efaproxiral is to increase the efficacy of certain chemotherapy drugs which have reduced efficacy against hypoxic tumours, and can thus be made more effective by increased offloading of oxygen into the tumour tissues.[4][5][6] No benefit was seen for efaproxiral in phase III clinical trials.[7] The increased oxygenation of tissues could theoretically also produce enhanced exercise capacity in feline, rat and canine models for approximately 100 min. immediately after a high dosage 45 min. intravenous infusion.[8] This has led World Anti-Doping Agency to categorise efaproxiral under a prohibited method to artificially enhance the uptake, transport or delivery of oxygen.[9] There is no existing evidence that efaproxiral can effectively enhance performance in humans.[10] Efaproxiral can be absorbed via transdermal, rectal, inhalation and gastrointestinal routes, though not at plasma concentrations great enough to alter the oxygen-haemoglobin dissociation curve.[11] Efaproxiral is explicitly excluded from the 2012 World Anti-Doping Agency list of Prohibited Substances and is explicitly included in the Prohibited Methods section M1 as a forbidden procedure to alter the oxygen-haemoglobin dissociation curve in order to allosterically modify haemoglobin.[12]

References

  1. Farace, Melikyan (2008). "Cognitive Dysfunction, Mood Disorders, and Fatigue". CANCER NEUROLOGY IN CLINICAL PRACTICE: 242–248. doi:10.1007/978-1-59745-412-4_7.
  2. [1]
  3. Kunert MP, Liard JF, Abraham DJ (August 1996). "RSR-13, an allosteric effector of haemoglobin, increases systemic and iliac vascular resistance in rats". Am. J. Physiol. 271 (2 Pt 2): H602–13. PMID 8770102.
  4. Donnelly ET, Liu Y, Rockwell S (March 2006). "Efaproxiral (RSR13) plus oxygen breathing increases the therapeutic ratio of carboplatin in EMT6 mouse mammary tumors". Exp. Biol. Med. (Maywood). 231 (3): 317–21. PMID 16514179.
  5. Engel RH, Kaklamani VG (April 2006). "Role of efaproxiral in metastatic brain tumours". Expert Rev Anticancer Ther. 6 (4): 477–85. doi:10.1586/14737140.6.4.477. PMID 16613536.
  6. Scott C, Suh J, Stea B, Nabid A, Hackman J (December 2007). landingpage.htm?issn=0277-3732&volume=30&issue=6&spage=580 "Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases" Check |url= value (help). Am. J. Clin. Oncol. 30 (6): 580–7. doi:10.1097/COC.0b013e3180653c0d. PMID 18091051.
  7. [2]
  8. Watanabe T; Takeda T; Omiya S; et al. (August 2008). "Reduction in hemoglobin-oxygen affinity results in the improvement of exercise capacity in mice with chronic heart failure". J. Am. Coll. Cardiol. 52 (9): 779–86. doi:10.1016/j.jacc.2008.06.003. PMID 18718428. Unknown parameter |author-separator= ignored (help)
  9. WADA 2009 Prohibited List
  10. Antonio Claudio Lucas da Nobrega (Feb 2002). "RSR13 and allosteric change in the hemoglobin-oxygen Afinity". Journal of Sports Medicine. 8. ISSN 1517-8692.
  11. Campanini, Bruno, Raboni, Mozzarelli (January 2003). "Oxygen Delivery by Allosteric Effectors of Hemoglobin, Blood Substitutes, and Plasma Expanders". Burger's Medicinal Chemistry, Drug Discovery and Development. doi:10.1002/0471266949.bmc048.
  12. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2012/WADA_Prohibited_List_2012_EN.pdf

Linked-in.jpg